• On June 8, 2026, Roche announced an exclusive global license and collaboration with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg (NX-5948), including a US$700 million upfront payment and potential milestones bringing the total deal value to up to US$2.30 billion, with shared development costs and a profit split in the United States.
• Beyond the headline payment, the agreement positions bexobrutideg as a cross-therapeutic asset spanning B‑cell malignancies, immunology and neurology, pairing Nurix’s degrader platform with Roche’s worldwide development and commercialization reach.
• Next, we’ll examine how this US$700 million upfront Roche partnership reshapes Nurix’s investment narrative around bexobrutideg’s multi-indication potential.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Nurix Therapeutics' Investment Narrative?

For Nurix, being a shareholder really comes down to believing that its targeted protein degradation pipeline, led by bexobrutideg, can convert scientific promise into commercially meaningful products before the cash burn becomes too painful. The Roche deal is a clear swing factor in that story: US$700 million upfront significantly strengthens the balance sheet and reduces funding risk, while Roche’s global reach could accelerate development across B cell cancers, immunology and neurology. In the near term, the key catalysts remain clinical readouts for bexobrutideg and other pipeline assets, plus closure of the Roche transaction, which is still subject to antitrust clearance. At the same time, Nurix is unprofitable, has seen losses widen, has diluted shareholders and trades on a rich sales multiple, so execution risk is front and center.

However, investors should be aware that the Roche partnership does not eliminate Nurix’s execution and dilution risks. According our valuation report, there's an indication that Nurix Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

Simply Wall St Community members currently converge around a single fair value near US$30.94 per share, even before factoring in the US$700 million Roche upfront that could reshape Nurix’s funding profile and pressure on future capital raises, reminding you that individual views can differ sharply and are worth comparing.

Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nurix Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Nurix Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.